Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.9 EUR | +5.45% | -1.69% | +6.62% |
Mar. 15 | Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development | MT |
2023 | Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results | MT |
Sales 2021 | 1.93M 2.06M | Sales 2022 | 1.9M 2.02M | Capitalization | 5.1M 5.44M |
---|---|---|---|---|---|
Net income 2021 | 1M 1.07M | Net income 2022 | - 0 | EV / Sales 2021 | 3.77 x |
Net cash position 2021 | 486K 517K | Net cash position 2022 | 421K 449K | EV / Sales 2022 | 2.47 x |
P/E ratio 2021 |
4.78
x | P/E ratio 2022 |
14
x | Employees | 7 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.51% |
1 day | +5.45% | ||
1 week | -1.69% | ||
Current month | +5.84% | ||
1 month | +16.00% | ||
3 months | -2.68% | ||
6 months | -14.20% | ||
Current year | +6.62% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 94-12-31 | |
Patrice Coffe
DFI | Director of Finance/CFO | 55 | 08-06-30 |
Chief Tech/Sci/R&D Officer | - | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jean-Luc Rivière
BRD | Director/Board Member | - | 12-06-25 |
Chief Executive Officer | 50 | 94-12-31 | |
Patrice Coffe
DFI | Director of Finance/CFO | 55 | 08-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 2.9 | +5.45% | 41,321 |
24-04-18 | 2.75 | -1.79% | 14,844 |
24-04-17 | 2.8 | -0.53% | 14,086 |
24-04-16 | 2.815 | -2.93% | 37,801 |
24-04-15 | 2.9 | +0.52% | 18,388 |
Real-time Euronext Paris, April 19, 2024 at 11:39 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+6.62% | 9.72M | |
-9.70% | 199B | |
+0.86% | 167B | |
+11.02% | 166B | |
+4.44% | 99.41B | |
+6.17% | 77.66B | |
+10.70% | 71.13B | |
-8.53% | 70.31B | |
-26.91% | 49.56B | |
-1.27% | 47.53B |
- Stock Market
- Equities
- ALKLA Stock